Roche’s Gavreto (pralsetinib) Receives the US FDA’s Approval for Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancers

December 2, 2020 Auto Bot Gavreto, receives, regulatory, US FDA’s Approval 0

Shots:

  • The approval is based on P-I/II ARROW study involve assessing Gavreto (400mg, qd) n people with rearranged during transfection (RET) fusion-positive NSCLC, RET-mutant MTC, RET fusion-positive thyroid cancer, and other RET-altered solid tumors
  • The study demonstrated durable clinical activity in people with/out prior therapy and regardless of RET alteration genotypes
  • Gavreto is a once-daily, oral precision therapy designed to selectively target RET alterations, including fusions and mutations

Click here ­to­ read full press release/ article | Ref: Roche | Image: Fierce Biotech

The post Roche’s Gavreto (pralsetinib) Receives the US FDA’s Approval for Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancers first appeared on PharmaShots.